Omnicell, Inc. (NASDAQ:OMCL) Shares Acquired by Guggenheim Capital LLC

Guggenheim Capital LLC grew its stake in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 168.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 7,659 shares of the company’s stock after purchasing an additional 4,807 shares during the period. Guggenheim Capital LLC’s holdings in Omnicell were worth $667,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Wipfli Financial Advisors LLC acquired a new position in shares of Omnicell in the 3rd quarter valued at about $25,000. Money Concepts Capital Corp acquired a new position in shares of Omnicell in the 3rd quarter valued at about $27,000. Van ECK Associates Corp acquired a new position in Omnicell in the 3rd quarter worth about $49,000. UMB Bank n.a. raised its holdings in Omnicell by 28.5% in the 3rd quarter. UMB Bank n.a. now owns 721 shares of the company’s stock worth $63,000 after purchasing an additional 160 shares during the period. Finally, Covestor Ltd raised its holdings in Omnicell by 424.2% in the 1st quarter. Covestor Ltd now owns 844 shares of the company’s stock worth $109,000 after purchasing an additional 683 shares during the period.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of analyst reports. Benchmark raised Omnicell from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a report on Monday, February 27th. KeyCorp reduced their price target on Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, March 2nd. Wells Fargo & Company reduced their price target on Omnicell from $71.00 to $65.00 and set an “overweight” rating for the company in a report on Tuesday, January 24th. SVB Leerink reaffirmed a “market perform” rating on shares of Omnicell in a report on Friday, January 27th. Finally, JPMorgan Chase & Co. reduced their price target on Omnicell from $140.00 to $57.00 and set a “neutral” rating for the company in a report on Friday, November 18th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.67.

Insider Activity

In other news, EVP Scott Peter Seidelmann sold 945 shares of the company’s stock in a transaction that occurred on Tuesday, December 27th. The stock was sold at an average price of $48.28, for a total value of $45,624.60. Following the completion of the sale, the executive vice president now directly owns 29,788 shares in the company, valued at $1,438,164.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Scott Peter Seidelmann sold 945 shares of the company’s stock in a transaction that occurred on Tuesday, December 27th. The stock was sold at an average price of $48.28, for a total value of $45,624.60. Following the completion of the sale, the executive vice president now directly owns 29,788 shares in the company, valued at $1,438,164.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joanne B. Bauer sold 13,115 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $54.24, for a total value of $711,357.60. Following the completion of the transaction, the director now owns 28,096 shares of the company’s stock, valued at $1,523,927.04. The disclosure for this sale can be found here. Insiders sold 18,496 shares of company stock worth $968,979 over the last ninety days. Corporate insiders own 2.76% of the company’s stock.

Omnicell Price Performance

OMCL stock opened at $52.93 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.06 and a quick ratio of 1.71. The business has a 50 day simple moving average of $54.84 and a 200-day simple moving average of $66.05. The firm has a market capitalization of $2.38 billion, a PE ratio of 529.30, a price-to-earnings-growth ratio of 5.88 and a beta of 0.89. Omnicell, Inc. has a 1 year low of $46.11 and a 1 year high of $138.50.

About Omnicell

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.